Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 9/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305374 | 1.00 | LMNA (0.54) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL163319 | 1.00 | LMNA (0.54) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL1442233 | 1.00 | LMNA (0.54) | LMNACYP2C19HSD17B10ACEREN | |
| Hydrochloric Acid SCHEMBL951618 | 0.98 | LMNA (0.53) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL3682815 | 0.94 | LMNA (0.49) | LMNACYP2C19HSD17B10ACE | |
| Hydrochloric Acid SCHEMBL27844215 | 0.92 | LMNA (0.47) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL6843118 | 0.86 | LMNA (0.41) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL8591233 | 0.84 | HTT (0.45) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL3817074 | 0.84 | HTT (0.45) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL30305372 | 0.84 | HTT (0.45) | LMNACYP2C19HSD17B10ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101969973-B | Inhibitors of cathepsin B | VIROBAY INC | 2015-07-22 | — | — | CN | claimed |
| CN-101969973-A | Inhibitors of cathepsin b | VIROBAY INC | 2011-02-09 | — | — | CN | claimed |
| CN-115611883-B | PI3K alpha inhibitor with double-ring structure, and preparation method and application thereof | 生物岛实验室 | 2025-03-28 | — | — | CN | disclosed |
| CN-115144487-B | Amino acid detection method | 宁波大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116036076-A | Application of lithium amino acid in preparation of medicine for treating manic mental diseases | 安域生物科技(杭州)有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115813913-A | Application of proline or isobutyric acid in preparation of auxiliary drugs of central nervous excitation drugs | 安域生物科技(杭州)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115144487-A | Detection method of amino acid | 宁波大学 | 2022-10-04 | — | — | CN | disclosed |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ABAC Therapeutics, S.L. (ES) | 2021-02-16 | — | — | US | disclosed |
| EP-3265456-B1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3490984-B1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | Abac Therapeutics Sl (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC Therapeutics, S.L. (ES) | 2019-06-13 | — | — | US | disclosed |
| WO-2018020004-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC THERAPEUTICS, S.L (ES) | 2018-02-01 | — | — | WO | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| CN-101969973-B | Inhibitors of cathepsin B | VIROBAY INC | 2015-07-22 | — | — | CN | disclosed |
| CN-103402516-A | Compounds useful as antiviral agents, compositions, and methods of use | FUZIANS BIOMEDICALS INC | 2013-11-20 | — | — | CN | disclosed |
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| CN-101969973-A | Inhibitors of cathepsin b | VIROBAY INC | 2011-02-09 | — | — | CN | disclosed |
| EP-2125718-B1 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-15 | — | — | EP | disclosed |
| CN-1829736-A | severe acute respiratory syndrome coronavirus | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ATAD2, ATAD2B, ATAD5 | LMNA 4467/4885CYP2C19 1130/4885HSD17B10 3416/4885 |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ATAD2, ATAD2B, ATAD5 | LMNA 4467/4885CYP2C19 1130/4885HSD17B10 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.